Systematic Reviews of Drug Treatments for Mental Illnesses

Follow the links below to find summaries of systematic reviews of the evidence for the effectiveness of drug treatments for mental illnesses.

Created January 2008

Printer friendly page

11 Resources Found
Results 1 to 11 displayed.
Title:   Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Tardive dyskinesia is a disfiguring and disabling movement disorder which is often caused by drugs used to treat schizophrenia. Several of the Cochrane reviews have summarised the effects of the many treatments used to manage these involuntary movements...
Date:   Oct 2005
Title:   Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Anti-psychotic drugs are the mainstay treatment for schizophrenia and similar psychotic disorders. Long-acting depot injections of drugs such as flupenthixol decanoate are extensively used as a means of long-term maintenance treatment.
Title:   Cholinergic medication for neuroleptic-induced tardive dyskinesia
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Drug-induced tardive dyskinesia is a common adverse effect of some antipsychotics, especially when these are given for an extended period of time. Tardive dyskinesia consists of involuntary repetitive movements, mainly in the oral region, but sometimes ...
Date:   May 2002
Title:   Sulpiride for schizophrenia
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   The aim of this review is to estimate the clinical efficacy and tolerability of sulpiride.
Title:   Miscellaneous treatments for neuroleptic-induced tardive dyskinesia
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Tardive dyskinesia is a disfiguring and disabling disorder of voluntary control of movement often caused by antipsychotic drugs. Several Cochrane reviews have summarised the effects of the many treatments used to manage these involuntary movements. This...
Date:   Jan 2003
Title:   Carbamazepine for schizophrenia
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Carbamazepine is an antiepileptic drug, which is also used as an adjunct to antipsychotics for schizophrenia. Although the original patient data from eight out of ten included studies could be re-analysed, we found no significant benefit of carbamazepin...
Date:   May 2007
Title:   Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   It is important to identify drugs, or drug strategies which can either prevent or reduce tardive dyskinesia. We undertook a comprehensive review of the impact of neuroleptic dose reduction and/or cessation, and specific neuroleptics as treatments for th...
Date:   Sep 2005
Title:   Calcium channel blockers for neuroleptic-induced tardive dyskinesia
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Antipsychotic medication is associated with adverse effects, including tardive dyskinesia which is characterised by abnormal, repetitive, involuntary facial movements. Calcium channel blockers, originally developed for use in cardiovascular disorders, h...
Date:   Oct 2003
Title:   Vitamin E for neuroleptic-induced tardive dyskinesia
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Having to take antipsychotic drugs for long periods of time can cause repetitive movements - often of the face and mouth. These are disfiguring and do not necessarily cease once medication is reduced or changed. Vitamin E has been evaluated for treating...
Date:   Aug 2001
Title:   Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Sometimes it is necessary to use medication to help stop aggressive or agitated behaviour that is thought to be caused by serious mental illness. Two ways of doing this are to give olanzapine as an injection into the muscle (IM ) or as a swiftly dissolv...
Date:   Feb 2005
Title:   Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Some limited evidence from trials suggest zuclopenthixol decanoate may prevent or postpone relapses better than other depot (long-lasting) drugs for schizophrenia, but it may have more adverse effects and more research is needed
Results 1 to 11 displayed.